Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million ...Middle East

PR Newswire - News
AACHEN, Germany, Aug. 4, 2022 /PRNewswire/ -- Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin ("RTX"). Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan...

Read More Details
Finally We wish PressBee provided you with enough information of ( Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million )

Apple Storegoogle play

Also on site :

Most viewed in News